Literature DB >> 12094850

Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.

F Baldi1, A M Morselli-Labate, R Cappiello, S Ghersi.   

Abstract

OBJECTIVE: For the long term maintenance treatment of reflux esophagitis several strategies have been proposed with the aim of reducing the daily dosage or the frequency of drug administration. However, the available clinical studies are scarce and are often not controlled or conducted on a reduced number of cases. We aimed to compare the efficacy of two doses of lansoprazole (15 mg once daily and 30 mg on alternate days) in maintaining endoscopic healing and symptom relief over a 6-month period.
METHODS: One hundred thirty-seven patients with Savary-Miller grades I-III reflux esophagitis healed after an 8-wk treatment with lansoprazole (30 mg daily) were divided into two main groups for a 6-month maintenance therapy period: lansoprazole, 15 mg once daily (group 15qd) and lansoprazole, 30 mg on alternate days (group 30qod). These two main groups were further subdivided according to the time of drug administration; morning (15qdm and 30qodm) and evening (15qde and 30qode). Each patient underwent esophagogastroduodenoscopy before entry into the study, after 8 wk of acute therapy, and after 6 months of maintenance therapy; 24-h esophageal-gastric pH monitoring was performed at baseline and during the last week of maintenance therapy.
RESULTS: At the end of the maintenance period the recurrence of esophagitis was observed in 12.1% of group 15qd patients and in 19.0% of group 30qod patients, without significant differences between the two groups. The frequency of patients without reflux symptoms after the 6-month period was the same for both groups; however, a significant increase of heartburn was observed in group 30qod patients (from 12.1% to 28.6%, p = 0.007). The time of drug administration (morning and evening) had no influence on the outcome of treatment. Both regimens significantly reduced esophageal acid exposure time and increased the median 24-h gastric pH.
CONCLUSIONS: Both long term lansoprazole regimens are equally effective in preventing the recurrence of esophagitis, independent of the modality of drug administration. The daily administration seems to have a better effect on the prevention of symptom recurrence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094850     DOI: 10.1111/j.1572-0241.2002.05666.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

Review 1.  Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.

Authors:  Fabio Baldi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.

Authors:  Norimasa Yoshida; Kazuhiro Kamada; Naoya Tomatsuri; Takahiro Suzuki; Tomohisa Takagi; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

3.  Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.

Authors:  Thomas O Kovacs; James W Freston; Marian M Haber; Barbara Hunt; Stuart Atkinson; David A Peura
Journal:  Dig Dis Sci       Date:  2009-03-07       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.